Amphista Therapeutics

CompanyUnited Kingdom

Amphista Therapeutics develops one asset, in phase 1 (AMX-883 in acute myeloid leukemia). Mostly small molecule; based in the United Kingdom.

1
Asset
Furthest stage: Phase 1; 0
Trials: 1
Signal

Pipeline

1

AMX-883
Promotes targeted protein degradation through a mechanism independent of cereblon and VHL.
Phase 1, Small molecule, acute myeloid leukemia

Full company profiles: pipeline, trials, funding and people.

In the full profile

Signals1
Similar companies3